Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An examination of short-term operating activity ratios reveals several noteworthy trends over the observed period. Generally, a decreasing trend is apparent in many efficiency metrics, particularly from 2022 through 2025. However, there are periods of fluctuation and some ratios demonstrate more stability than others. The analysis below details observations for specific ratios and related themes.
- Inventory Management
- Inventory turnover exhibits a consistent decline from 2.74 in March 2022 to 2.46 in December 2025. This suggests a lengthening of the time it takes to sell inventory. Correspondingly, the average inventory processing period increases from 133 days to 148 days over the same timeframe, reinforcing the observation of slower inventory movement. The slight increase in inventory turnover in the final quarter of 2025 may indicate a seasonal effect or a deliberate effort to reduce stock levels.
- Receivables Management
- Receivables turnover generally decreased from 5.49 to 5.52 over the period, with some quarterly volatility. The average receivable collection period remained relatively stable, fluctuating between 58 and 69 days. While not a dramatic shift, the slight decrease in turnover coupled with a consistent collection period suggests a potential slowing in the rate at which receivables are converted to cash. The increase to 6.24 in December 2022 and 5.92 in March 2023 are notable peaks, followed by a return to more typical levels.
- Payables Management
- Payables turnover demonstrates a more pronounced pattern of fluctuation. It peaked at 5.16 in September 2022 before declining to 3.72 in December 2023. While it recovered somewhat to 3.72 in December 2025, it remains lower than earlier values. The average payables payment period increased from 86 days in March 2022 to 98 days in December 2024, before decreasing slightly to 98 days in December 2025. This indicates a lengthening in the time taken to settle obligations to suppliers, potentially reflecting a strategy to manage cash flow or negotiate extended payment terms.
- Overall Operating Cycle & Cash Conversion Cycle
- The operating cycle generally increased from 199 days in March 2022 to 214 days in December 2025, reflecting the combined effect of changes in inventory and receivables. The cash conversion cycle experienced more significant fluctuations, peaking at 135 days in June 2025. The increase in the cash conversion cycle suggests a longer time between investing in inventory and collecting cash from sales. The decrease to 116 days in December 2025 may indicate improved cash management practices or a change in business conditions.
- Working Capital Turnover
- Working capital turnover exhibited substantial volatility. A significant peak of 8.86 was observed in June 2023, followed by a decline to 4.28 in December 2025. This suggests a considerable change in the efficiency with which working capital is utilized to generate sales. The fluctuations may be linked to specific business events or strategic decisions impacting working capital management.
In summary, the observed trends suggest a general slowdown in operating efficiency, particularly concerning inventory and payables management. While receivables management remained relatively stable, the overall lengthening of the operating and cash conversion cycles warrants further investigation. The volatility in working capital turnover highlights the dynamic nature of the company’s short-term asset and liability management.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Inventories, excludes inventories classified in Other assets | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Inventory turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Inventories, excludes inventories classified in Other assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Inventory turnover exhibited a generally declining trend over the observed period, spanning from March 31, 2022, to December 31, 2025. While fluctuations occurred, the ratio consistently decreased from an initial value of 2.74 to a final value of 2.46. This suggests a lengthening of the time it takes to sell inventory.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The inventory turnover ratio began at 2.74 and showed initial improvement, peaking at 3.10 in September 2022. However, it concluded the year at 2.95, indicating a slight decrease from the highest point within the year. Cost of sales remained relatively stable during this period, while inventory levels fluctuated.
- 2023 Performance
- Throughout 2023, the ratio experienced a consistent downward trajectory, moving from 2.72 in March to 2.54 by year-end. This decline coincided with a gradual increase in inventory levels and relatively stable cost of sales. The decrease suggests a potential slowdown in sales relative to inventory purchases.
- 2024 and Early 2025
- The downward trend continued into 2024, reaching a low of 2.39 in June. A slight recovery to 2.49 was observed by December 2024, but this was short-lived. The ratio further decreased to 2.25 in March 2025, before a modest increase to 2.46 by the end of the period. Inventory levels remained elevated throughout this timeframe, while cost of sales showed some variability.
- Cost of Sales and Inventory Relationship
- A review of cost of sales and inventory levels reveals a complex relationship. While cost of sales generally decreased over the period, inventory levels remained relatively high and even increased in some quarters. This disparity likely contributed to the observed decline in inventory turnover. The significant increase in cost of sales in the final period (December 31, 2025) coincided with a corresponding increase in the inventory turnover ratio.
Overall, the observed trend suggests a potential issue with inventory management or a slowdown in demand for the company’s products. Further investigation into the factors driving these changes is warranted.
Receivables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Accounts receivable, net of allowance for doubtful accounts | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Receivables turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Accounts receivable, net of allowance for doubtful accounts
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. An initial upward trend is noted in the first half of the period, followed by stabilization and then a subsequent shift in direction.
- Initial Trend (Mar 31, 2022 – Jun 30, 2022)
- The receivables turnover ratio increased from 5.49 to 5.93, indicating a more efficient collection of receivables during this timeframe. This suggests a shortening of the average collection period.
- Peak and Subsequent Decline (Jul 1, 2022 – Dec 31, 2022)
- The ratio continued to rise, peaking at 6.27 in December 2022. This suggests continued improvement in the efficiency of collecting receivables. However, the increase was modest.
- Stabilization and Decline (Jan 1, 2023 – Jun 30, 2023)
- The first half of 2023 saw a decline in the receivables turnover ratio, falling from 5.56 to 5.29. This indicates a potential lengthening of the average collection period and a slight decrease in the efficiency of converting receivables into cash.
- Fluctuation and Recovery (Jul 1, 2023 – Dec 31, 2024)
- The ratio experienced fluctuations, increasing to 5.81 by September 2023, then decreasing to 5.37 by March 2024. A subsequent increase to 6.24 in December 2024 suggests a recovery in collection efficiency.
- Recent Trend (Jan 1, 2025 – Dec 31, 2025)
- The ratio decreased to 5.92 in March 2025, then declined further to 5.30 in September 2025, before recovering slightly to 5.52 by December 2025. This recent trend suggests a potential weakening in receivables collection efficiency, although the final value indicates a partial rebound.
Overall, the receivables turnover ratio demonstrates a cyclical pattern. While periods of improvement in collection efficiency are observed, there are also instances of decline. The fluctuations may be attributable to changes in credit policies, customer payment behavior, or the composition of sales.
Payables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Trade accounts payable | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Payables turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Trade accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The payables turnover ratio exhibits fluctuations over the observed period, generally indicating a moderate level of efficiency in managing supplier credit. An initial upward trend is followed by a period of relative stability and then a decline.
- Overall Trend
- The payables turnover ratio began at 4.25 and generally increased through the first three quarters of 2022, peaking at 5.16. Subsequently, the ratio decreased, reaching a low of 3.53 in the third quarter of 2025. The most recent period shows a slight recovery to 3.72.
- 2022 Performance
- Throughout 2022, the ratio demonstrated improvement, suggesting the company was becoming more efficient in paying its suppliers. The increase from 4.25 in March to 5.16 in September indicates a faster conversion of payables into payments, potentially due to improved cash flow management or negotiated payment terms.
- 2023-2024 Fluctuations
- The period from 2023 to 2024 shows more variability. The ratio remained relatively stable in the first half of 2023, then decreased in the latter half. This pattern continued into 2024, with no clear directional trend. The ratio hovered around the 4.0 to 4.5 range, indicating consistent, but not improving, payables management.
- Recent Decline (2025)
- A noticeable downward trend emerges in 2025. The ratio declined from 3.98 in the first quarter to 3.53 in the third quarter, suggesting a slowing in the rate at which payables are being settled. The slight increase to 3.72 in the final quarter of 2025 may indicate a temporary stabilization, but the overall trend remains negative for the year.
- Relationship to Cost of Sales
- While the payables turnover ratio fluctuates, it generally moves inversely with cost of sales. Periods of higher cost of sales often correspond with lower payables turnover, and vice versa. This suggests the company adjusts its payment practices in response to changes in purchasing activity. However, the relationship is not perfectly consistent.
- Payables Levels
- Trade accounts payable remained relatively stable between US$3.371 million and US$4.264 million for most of the period. A slight increase in payables is observed towards the end of the period, which may contribute to the declining payables turnover ratio.
Working Capital Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||
| Working capital | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Working capital turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicate a generally decreasing trend through the end of 2022, followed by a period of volatility and then a decline towards the end of the observation window.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The working capital turnover ratio began at 6.09 in March 2022, increasing to 6.39 in June 2022. Subsequently, the ratio decreased to 5.58 by September 2022 and further declined to 5.16 by December 2022. This suggests a gradual reduction in the efficiency with which working capital was being utilized to generate sales during this timeframe.
- Volatility and Peak (Mar 31, 2023 – Sep 30, 2023)
- A significant increase was observed in March 2023, with the ratio reaching 5.63. This was followed by a substantial jump to 8.86 in June 2023, representing the highest value in the observed period. The ratio then decreased to 6.69 by September 2023, indicating a potential stabilization after the peak but remaining above the levels seen in the latter half of 2022.
- Recent Trend (Dec 31, 2023 – Dec 31, 2025)
- The ratio increased to 9.29 in December 2023, before decreasing to 5.14 in March 2024. It then showed a slight increase to 5.86 in June 2024, followed by 6.19 in September 2024 and remaining at 6.19 in March 2025. A notable decline occurred in the latter half of 2025, with the ratio falling to 3.39 in September 2025 and recovering slightly to 4.28 by December 2025. This recent downward trend suggests a diminishing efficiency in working capital utilization towards the end of the period.
Overall, the working capital turnover ratio demonstrates considerable variability. While periods of increased efficiency are evident, the latter portion of the observed timeframe indicates a potential weakening in the relationship between working capital and sales generation. Further investigation into the underlying drivers of these fluctuations, such as changes in inventory management, accounts receivable collection periods, and accounts payable payment terms, would be beneficial.
Average Inventory Processing Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibited a generally increasing trend over the observed timeframe, beginning in the first quarter of 2022 and continuing through the second quarter of 2025. While fluctuations occurred, the overall movement indicates a lengthening of the time required to convert inventory into sales.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The average inventory processing period began at 133 days in March 2022, decreased to 119 days by June 2022, and remained relatively stable around 118-124 days through the end of 2022. This initial period suggests efficient inventory management, with a slight improvement in processing time during the second quarter.
- Increasing Trend (Mar 31, 2023 – Jun 30, 2025)
- Starting in the first quarter of 2023, the average inventory processing period began a consistent upward trajectory. It increased from 134 days in March 2023 to a peak of 162 days in the second quarter of 2025. This indicates a slowing in the rate at which inventory is sold and replaced.
- Recent Fluctuations (Sep 30, 2024 – Jun 30, 2025)
- The period from September 2024 to June 2025 shows some variability. The processing period reached 149 days in September 2024, decreased slightly to 147 days in December 2024, then increased to 162 days in June 2025. This suggests potential short-term disruptions or adjustments in inventory management practices.
- Inventory Turnover Correlation
- The observed increase in the average inventory processing period correlates with a decreasing trend in inventory turnover. As inventory turnover declined from 2.74 in March 2022 to 2.25 in June 2025, the time to process inventory correspondingly lengthened. This inverse relationship is expected, as lower turnover rates directly translate to longer processing periods.
The lengthening of the average inventory processing period warrants further investigation to determine the underlying causes. Potential factors could include changes in product mix, shifts in demand, supply chain disruptions, or adjustments to inventory management strategies. A sustained increase in this metric may indicate inefficiencies in inventory control and could potentially lead to increased holding costs and the risk of obsolescence.
Average Receivable Collection Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited fluctuations over the observed timeframe, generally remaining within a relatively narrow range. An initial decreasing trend is noted from the first quarter of 2022 through the final quarter of 2022, followed by increased variability in subsequent periods.
- Overall Trend
- The collection period began at 66 days in March 2022, decreased to a low of 58 days by December 2022, and then increased to 69 days by June 2023. The period subsequently decreased to 58 days in December 2023 before rising again to 69 days in September 2025, ultimately concluding at 66 days in December 2025. This suggests a cyclical pattern with no clear, sustained directional trend.
- Short-Term Fluctuations
- A consistent decrease was observed throughout 2022, indicating improved efficiency in collecting receivables. However, the first half of 2023 showed a reversal of this trend, with the collection period increasing to 69 days. The period then stabilized somewhat, fluctuating between 62 and 68 days through the remainder of 2023 and into 2024. A renewed increase occurred in 2025, peaking at 69 days before settling back to 66 days.
- Recent Performance
- The most recent two periods (September 30, 2025 and December 31, 2025) show a slight decrease from 69 days to 66 days. While this is a minor change, it could indicate a potential stabilization or a return to the lower end of the observed range. Further monitoring is needed to confirm this.
- Comparison to Initial Period
- The average receivable collection period concluded at 66 days in December 2025, mirroring the value recorded in March 2022. This suggests that despite the interim fluctuations, the company’s efficiency in collecting receivables has, on balance, remained consistent over the analyzed period.
The observed variations in the average receivable collection period warrant continued monitoring to identify potential underlying causes, such as changes in credit policies, customer payment behavior, or the composition of outstanding receivables.
Operating Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle, along with its component parts, exhibits discernible trends over the observed period. Generally, there is an increasing trend in both the average inventory processing period and the average receivable collection period, which consequently extends the overall operating cycle.
- Average Inventory Processing Period
- The average inventory processing period demonstrates a generally increasing trend throughout the analyzed timeframe. Starting at 133 days in March 2022, it decreased to 118 days by September 2022, before steadily increasing to 162 days in June 2025. While fluctuations occur, the period consistently remains above the initial value observed in March 2022, suggesting a lengthening time required to convert inventory into finished goods and make them available for sale. A slight decrease is observed in the final period, ending at 148 days in December 2025.
- Average Receivable Collection Period
- The average receivable collection period also shows an overall upward trend, though less pronounced than that of the inventory processing period. Beginning at 66 days in March 2022, it decreased to a low of 58 days in December 2022. Subsequently, it increased to 69 days in June 2025, before decreasing slightly to 66 days in December 2025. This indicates a gradual lengthening in the time taken to collect payments from customers.
- Operating Cycle
- The operating cycle, calculated as the sum of the inventory processing and receivable collection periods, reflects the combined effect of the trends in its components. It increased from 199 days in March 2022 to 230 days in June 2025, representing a substantial extension of the time required to complete a full operating cycle. A decrease is observed in the final period, with the operating cycle ending at 214 days in December 2025. The overall trend suggests a reduced efficiency in converting raw materials into cash from sales.
The consistent increases in both component periods contribute to a longer operating cycle, potentially indicating challenges in inventory management, credit policies, or collection processes. The slight decreases observed in the final periods may suggest recent efforts to improve these areas, but the overall trend remains upward over the majority of the analyzed period.
Average Payables Payment Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. An initial decreasing trend was followed by periods of relative stability and subsequent increases.
- Overall Trend
- From the first quarter of 2022 through the fourth quarter of 2023, the average payables payment period generally decreased, then stabilized, before increasing significantly in late 2024 and early 2025. The period began at 86 days, decreased to a low of 71 days, and then rose to 98 days before settling at 98 days in the final reported quarter.
- Initial Decreasing Phase (Q1 2022 - Q3 2022)
- A consistent decline in the average payables payment period was observed during the first three quarters of 2022, moving from 86 days to 71 days. This suggests the entity was settling its obligations to suppliers more quickly during this timeframe.
- Stabilization and Fluctuations (Q4 2022 - Q3 2023)
- The period from the fourth quarter of 2022 through the third quarter of 2023 showed relative stability, with the average payables payment period fluctuating between 75 and 84 days. This indicates a consistent, though not rapidly changing, payment pattern to suppliers.
- Increasing Trend (Q4 2023 - Q1 2025)
- Beginning in the fourth quarter of 2023, the average payables payment period began to increase, reaching 98 days by the fourth quarter of 2024. This trend continued into the first quarter of 2025, peaking at 103 days, before decreasing slightly to 98 days in the final reported quarter. This suggests a lengthening in the time taken to settle obligations to suppliers.
- Recent Performance (Q1 2024 - Q1 2025)
- The most recent six quarters demonstrate a clear upward trend in the average payables payment period, increasing from 81 days to 98 days, with a peak of 103 days. This could indicate a shift in supplier relationships, changes in credit terms, or a deliberate strategy to manage cash flow.
The observed changes in the average payables payment period warrant further investigation to understand the underlying drivers and potential implications for the entity’s financial health and supplier relationships.
Cash Conversion Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity of the company, as measured by its cash conversion cycle and component ratios, exhibits notable fluctuations over the observed period. Generally, the cash conversion cycle lengthened from early 2022 through mid-2023, before showing some signs of stabilization and then increasing again into early 2025.
- Average Inventory Processing Period
- The average time to process inventory generally increased throughout the period. Starting at 133 days in March 2022, it decreased to 118 days by September 2022, then trended upwards, reaching 162 days in June 2025. This suggests a potential slowdown in inventory turnover or an increase in inventory levels held by the company. The increase in the latter half of the period warrants further investigation to determine if it is due to strategic decisions, supply chain disruptions, or decreased demand.
- Average Receivable Collection Period
- The average number of days to collect receivables remained relatively stable between 58 and 69 days for most of the period. There was a slight increase from 58 days in December 2022 to 69 days in June 2023, followed by a decrease to 66 days by December 2025. This indicates consistent, though slightly variable, efficiency in collecting payments from customers. The fluctuations are within a manageable range and do not suggest significant issues with credit policies or customer payment behavior.
- Average Payables Payment Period
- The average time taken to pay suppliers showed more pronounced variability. It began at 86 days in March 2022, decreased to 71 days by September 2022, then increased to 89 days by December 2022. A further increase was observed, peaking at 103 days in September 2025. This suggests the company has been strategically managing its payment terms with suppliers, potentially taking advantage of extended credit periods. The increase in the payables period in the latter part of the period could be a deliberate tactic to improve cash flow, but should be monitored to ensure it does not strain supplier relationships.
- Cash Conversion Cycle
- The cash conversion cycle initially decreased from 113 days in March 2022 to 93 days in December 2022. However, it then increased significantly to 135 days in June 2025. This lengthening cycle is primarily driven by the increasing inventory processing period, partially offset by fluctuations in the receivables and payables periods. A longer cash conversion cycle generally indicates that the company is tying up more cash in its operations, which could potentially impact liquidity. The recent increase suggests a need to review inventory management practices and optimize working capital.
Overall, the observed trends suggest a dynamic operating environment. While the company demonstrates some flexibility in managing its payables, the increasing inventory processing period is a key area to monitor. Further analysis should focus on the underlying reasons for these changes and their potential impact on the company’s financial performance and liquidity.